Prosecution Insights
Prosecution Insights
Technology area: Medical Devices & Mechanical Engineering
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sinaptica Therapeutics Inc. operates within the Medical Devices & Mechanical Engineering technology area and currently has 1 pending office action. This single action is located within 1 distinct art unit, showing the technical focus for the company's current patenting activities. Such a portfolio structure allows for a specific approach to intellectual property development within this field. The focus on 1 distinct art unit suggests that the company is prioritizing a technological niche.
The prosecution is handled by 1 distinct examiner, meaning the company's immediate success depends on a single point of contact at the patent office. EDWARDS, PHILIP CHARLES is the busiest examiner for the portfolio, managing 1 busiest examiner pending action. Because this examiner holds the entirety of the company's pending workload, understanding their specific examination patterns is critical for the company's strategy. The resolution of this 1 pending office action will be the determining factor for the company's current progress in the Medical Devices & Mechanical Engineering sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDWARDS, PHILIP CHARLES | 1 | 85.1% | +15.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18643609 | SYSTEMS AND METHODS FOR PROVIDING PERSONALIZED TARGETED NON-INVASIVE STIMULATION TO A BRAIN NETWORK | EDWARDS, PHILIP CHARLES | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18643609 | SYSTEMS AND METHODS FOR PROVIDING PERSONALIZED TARGETED NON-INVASIVE STIMULATION TO A BRAIN NETWORK | EDWARDS, PHILIP CHARLES | 14d |
| Art Unit | Apps |
|---|---|
| 3792 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18643609 | SYSTEMS AND METHODS FOR PROVIDING PERSONALIZED TARGETED NON-INVASIVE STIMULATION TO A BRAIN NETWORK | EDWARDS, PHILIP CHARLES | 3792 | §103 | Final Rejection | 14d | Pending | Apr 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial